Showing results (1-10 of 280) with videos related to
Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|January 1, 1987
Acetylation and oxidation phenotypes in malignant lymphomaP A Philip, H J Rogers, P G HarperCancer Chemotherapy and Pharmacology|January 1, 1989
Effect of cancer chemotherapy on dapsone N-acetylation in manP A Philip, P G Harper, H J RogersEuropean Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulinL D Lewis, L C Burton, P G Harper, et al.British Journal of Clinical Pharmacology|November 1, 1990
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolismL D Lewis, D L Fitzgerald, P G Harper, et al.British Journal of Clinical Pharmacology|December 1, 1987
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteersP A Philip, C A James, H J RogersBritish Journal of Clinical Pharmacology|April 1, 1984
A rapid method for determination of acetylation phenotype using dapsoneP A Philip, M S Roberts, H J RogersEuropean Journal of Clinical Pharmacology|January 1, 1989
The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizersP A Philip, C A James, H J RogersBritish Journal of Clinical Pharmacology|June 1, 1987
Influence of age, sex and body weight on the dapsone acetylation phenotypeP A Philip, S L Gayed, H J Rogers, et al.British Journal of Clinical Pharmacology|March 1, 1987
Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancerH C Gillies, D Herriott, R Liang, et al.Carcinogenesis|September 1, 1984
Genetically determined debrisoquine oxidation capacity in bladder cancerR A Cartwright, P A Philip, H J Rogers, et al.Pageof 28